eMed has entered a partnership with Scripps Research Translational Institute to advance a study to assess Covid-19 rebound following treatment.

Funded by the US National Institutes of Health (NIH), the at-home study will enrol up to 800 Covid-19-patients.

It will assess how frequently and why some patients who receive Pfizer’s oral anti-viral pill, Paxlovid, or who recuperate naturally from the virus ‘rebound’ to having symptoms or test positive for Covid-19.

People who use the Telehealth Kit of eMed to test and get a quick medical assessment for treatment with the oral antiviral can take part in the study. 

Each subject who receives the kit will be observed for two weeks for viral clearance and symptoms or disease rebound.

The study was created after observing Covid-19 patients reporting symptoms or the return of virus positivity following administration of oral antiviral treatments. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The initial data from the study is anticipated to be available in the coming weeks.

The NIH funding for Scripps will aid in expediting and progressing the study to enrol more subjects and to more precisely assess if the rebound is linked to specific viral immune responses or is viral variant dependent.

eMed chief science officer Michael Mina said: “The importance of understanding how frequently people who are treated for Covid-19 recover completely or rebound back to virus positivity cannot be overstated. 

“Effective treatments for Covid-19 are among the most important tools humans have to get out of this pandemic. 

“Knowing who stands to benefit the most from treatment, and knowing if rebound of symptoms is associated with different health outcomes or onward transmission is of massive individual and public health importance.”